USD0.000æéå€ååŒÂ  (ET)
270.79MæäŸ¡ç·é¡
14.56çŽè¿12ã¶æPER
äž»èŠããŒã¿
3.320å§å€
3.410é«å€
648.54Kåºæ¥é«
14.56çŽè¿12ã¶æPER
12.06äºæ³PER
--çŽè¿12ã¶æé
åœ
0.82%売買å転ç
3.320忥çµå€
3.210å®å€
1.48M売買代é
31.60æ ªäŸ¡åçç
3.28PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
19.05%ç·è³ç£å©çç
14.69052é±é«å€
1.09åºæ¥é«æ¯ç%
8.55MçŽå©ç
79.46Mæ ªåŒæ°
0.23351æ ªåœããå©çïŒEPSïŒ
2.19ããŒã¿å€
27.07%èªå·±è³æ¬å©çç
4.16052é±å®å€
6.02%æ¯ãå¹
63.47%ç²å©çç
270.79MæäŸ¡ç·é¡
-1.71ãªã¹ã¯ãªã¿ãŒã³
3.01%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Niagen Bioscience Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž78äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯12.42ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Niagen Bioscience Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Niagen Bioscience Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Niagen Bioscience Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Niagen Bioscience Inc
NAGE
6
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
ææšî
ææš
売ã(1)
äžç«(3)
è²·ã(2)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Niagen Bioscience Incã®äŒæ¥æ
å ±î
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Companyâs Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
äŒæ¥ã³ãŒãNAGE
äŒæ¥åNiagen Bioscience Inc
æé«çµå¶è²¬ä»»è
ãCEOãFried (Robert N)
ãŠã§ããµã€ãhttps://www.niagenbioscience.com/
æ ªäž»çµ±èšî
ãããã質å
Niagen Bioscience IncïŒNAGEïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNiagen Bioscience IncïŒNAGEïŒã®çŸåšã®æ ªäŸ¡ã¯3.40ã§ãã
Niagen Bioscience Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNiagen Bioscience Incã®ãã£ãã«ãŒã·ã³ãã«ã¯NAGEã§ãã
Niagen Bioscience Incã®52é±é«å€ã¯ãããã§ããïŒ
îNiagen Bioscience Incã®52é±é«å€ã¯14.69ã§ãã
Niagen Bioscience Incã®52é±å®å€ã¯ãããã§ããïŒ
îNiagen Bioscience Incã®52é±å®å€ã¯4.16ã§ãã
Niagen Bioscience Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îNiagen Bioscience Incã®æäŸ¡ç·é¡ã¯270.15Mã§ãã
Niagen Bioscience Inc (NAGE) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNiagen Bioscience IncïŒNAGEïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯12.42ã§ãã
Niagen Bioscience Inc (NAGE) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNiagen Bioscience IncïŒNAGEïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯0.22ã§ãã